Evotec SE Sponsored ADR
(NASDAQ: EVO)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

4.260

+0.210 (+5.19%)
Range 4.170 - 4.265   (2.28%)
Open 4.200
Previous Close 4.050
Bid Price 10.800
Bid Volume 11
Ask Price 11.300
Ask Volume 8
Volume 86,945
Value -
Remark
Delayed prices. Updated at 26 Jul 2025 04:00.
Data powered by
View All Events

Share your investing ideas
Please login to view stock data and analysis